Walleye Capital’s AbCellera Biologics ABCL Stock Holding History

Walleye Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$151K	Sell	43,200 -173,300	-80%	-$624K	﹤0.01%	3491
2025 Q4	$740K	Sell	216,500 -10,100	-4%	-$45.1K	﹤0.01%	2664
2025 Q3	$1.14M	Buy	+226,600	New	+$999K	﹤0.01%	1989
2024 Q1	–	Sell	-31,100	Closed	-$178K	–	5360
2023 Q4	$178K	Buy	31,100 +30,200	+3,356%	+$140K	﹤0.01%	3745
2023 Q3	$4.14K	Sell	900 -600	-40%	-$3.65K	﹤0.01%	4619
2023 Q2	$9.69K	Buy	+1,500	New	+$10.2K	﹤0.01%	3914
2022 Q4	–	Sell	-1,700	Closed	-$17K	–	3123
2022 Q3	$17K	Buy	+1,700	New	+$18.7K	﹤0.01%	2744

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ABCL Position: Q1 2026 in Review

Walleye Capital reduced its AbCellera Biologics (ABCL) stake by 96% in Q1 2026, selling an estimated $861K and leaving 9,780 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3986.

Walleye Capital first reported a position in ABCL in Q1 2021 and has held it in 6 quarters since. The position peaked at $852K in Q4 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Walleye Capital held 9,780 shares of AbCellera Biologics worth $34.1K as of Q1 2026.
Walleye Capital sold 239,270 AbCellera Biologics shares in Q1 2026, an estimated $861K.
AbCellera Biologics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3986 holding.
Walleye Capital first reported a position in AbCellera Biologics in Q1 2021 and has held it in 6 quarters since.
Walleye Capital's AbCellera Biologics position peaked at $852K in Q4 2025.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.